PRAME (preferentially expressed antigen in melanoma), typically expressed in normal testis and exhibiting abnormal expression across many cancer types, has garnered significant attention in UM research due to its association with negative prognostic factors, where approximately 25% of UM tumors expressed PRAME in association with aneuploidy, metastasis and poor patient outcome [122,123,124]. This evidence concerns the gene PRAME and melanoma.